Pharmacogenetics research on the relationship between CYP2D6 polymorphisms and the efficacy of tamoxifen in early BC has shown a strong relationship between a patient’s capacity to metabolise tamoxifen and treatment outcome18. This evidence concerns the gene CYP2D6 and breast cancer.